Therapeutic Strategies for Cardiovascular-Kidney-Metabolic Syndrome: Addressing the Interwoven Triad of Heart Failure, Chronic Kidney Disease, and Diabetes
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc and Eli Lilly and Company.
Click Here to Manage Email Alerts
CE Activity Release Date: January 6, 2025
CE Activity Expiration Date: January 5, 2026
Time to Complete activity: 1 hour
Activity Description
Delve into the cutting-edge world of Cardiovascular-Kidney-Metabolic (CKM) Syndrome management in this CKM Dialogues previously recorded LIVE. This dynamic, expert-led, evidence-driven CME activity sheds light on the latest strategies for tackling CKM syndrome—a complex condition at the intersection of heart failure, chronic kidney disease, and type 2 diabetes. While individual guidelines exist for each disease, comprehensive guidance on managing their overlap is limited. CKM Dialogues LIVE brings together a multidisciplinary team of experts to bridge this gap with real-world insights and discussions on emerging therapies.
In this 60-minute session, Therapeutic Strategies for Cardiovascular-Kidney-Metabolic Syndrome: Addressing the Interconnected Triad of Heart Failure, Chronic Kidney Disease, and Diabetes, you'll explore the metabolic mechanisms driving CKM syndrome and examine current and novel treatments. Learners will be empowered to rethink treatment approaches and tailor therapies for the best patient outcomes.
This activity is derived from an independent satellite symposium at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, originally held on December 12, 2024.
Target Audience
This activity is intended for primary care physicians and other members of the multidisciplinary, interprofessional healthcare team in the U.S who care for patients with cardiovascular-kidney-metabolic syndrome.
Educational Objectives
After completing this CE activity, the participant should be better able to:
- Describe the complex interplay between CKD, HF, and T2D in the context of cardiovascular-kidney-metabolic syndrome.
- Analyze the epidemiological trends and pathophysiological mechanisms underlying the interconnectedness of HF, CKD, and T2D, and their implications for patient prognosis and quality of life.
- Evaluate the current evidence base supporting emerging therapeutic strategies, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone synthase inhibitors (ASIs), for managing cardiovascular-kidney-metabolic syndrome, with a focus on their potential to mitigate morbidity and mortality.
- Formulate evidence-based treatment plans for patients with cardiovascular-kidney-metabolic syndrome that consider the complex interactions between HF, CKD, and T2D to enhance patient quality of life.
Agenda
- Introduction
- Exploring the Connections Between CKD, HF, T2D
- Unveiling Epidemiological Trends and Pathophysiological Links
- Emerging Therapeutic Strategies for CKM Syndrome
- Tailoring Treatment for CKM syndrome
- Q&A with Expert Faculty
Accreditation, Support and Credit
This activity is provided by
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
EBAC Credit
Medical Learning Institute Inc is an EBAC® accredited provider effective October 2023. EBAC holds an agreement on mutual recognition of substantial equivalency with the Accreditation Council of CME (ACCME) and converts certificates for live educational events in the US, issued by ACCME accredited providers to European participants, in EBAC certificates (on request of the participants).
Dietitian Continuing Professional Education Units (CPEUs)
Medical Learning Institute Inc is a Continuing Professional Education (CPE) Accredited provider with the Commission on Dietetic Registration (CDR).
Completion of this RD/DTR profession specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60-minute hour = 1 CPEU). RDs and DTRs are to select activity type 102 in their Activity Log. Performance Indicator selection is at the learner’s discretion.
CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activity/material.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) toward
AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 5, 2026. PAs should only claim credit commensurate with the extent of
their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.5 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
UAN: JA0007322-0000-25-003-H01-P
Support Statement
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc and Eli Lilly and Company.
Disclosure & Conflict of Interest Policy
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Jay H. Shubrook, DO, FACOFP, FAAFP
Professor Primary Care Department
Diabetologist
Touro University California
College of Osteopathic Medicine
Vallejo, CA, USA
Jay H. Shubrook, DO, FACOFP, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk
Other: Member of American Diabetes Association, American College of Diabetology (Chair of the Executive Board), American College of Osteopathic Family Physicians, American Academy of Family Physicians, American Osteopathic Association and the Global NASH Council.
The following relationships have ended within the last 24 months:
Consultant/Advisor: Nevro (ended 6/2023), Sanofi (ended)
Planner/Presenter
Jennifer B. Green, MD
Professor of Medicine
Division of Endocrinology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC, USA
Jennifer B. Green, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Lilly, Mineralys, Novo Nordisk, Pfizer, Valo, Vertex
Research Funding: Bluedrop, Boehringer Ingelheim, Lilly, Merck, Roche
Other: Member of the American Diabetes Association, Endocrine Society, European Association for the Study of Diabetes. Associate editor for Diabetes Care.
Planner/Presenter
Pam R. Taub, MD, FACC, FASPC
Professor of Medicine
Director of Preventive Cardiology
Founder and Director of Step Family Cardiac Rehabilitation and Wellness Center
University of California, San Diego
La Jolla, CA, USA
Pam R. Taub, MD, FACC, FASPC, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Amgen, Bayer, Boehringer Ingelheim, Edwards, Esperion, Jazz, Lilly, Medtronic, Merck, Novartis, Novo Nordisk, Sanofi
Contracted Researcher: Amgen, Merck, Novartis
The following relationships have ended within the last 24 months:
Consultant/Advisor: Amarin (ended 4/2024)
Contracted Researcher: Argenx (ended 1/2024)
Planner/Presenter
Matthew R. Weir, MD
Professor and Chief, Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, MD, USA
Matthew R. Weir, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Mineralys, Novo Nordisk
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physician, If requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
For EBAC® Participants: If you wish to receive an EBAC Certificate, you must complete another online evaluation. Upon completion, you will receive a code. Email this code to mvu@mlieducation.org and your certificate will be sent to you. Please access this short survey here: https://mli.link/ebaceval
ABOUT THIS ACTIVITY
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2025 Medical Learning Institute, Inc | All Rights Reserved